Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 93 for

Edit search filters
  1. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Rochester, MN

  2. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  3. Bendamustine Hydrochloride And Rituximab With Or Without Bortezomib Followed By Rituximab With Or Without Lenalidomide In Treating Patients With High-Risk Stage II, Stage III, Or Stage IV Follicular Lymphoma

    Rochester, MN

  4. Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP In Newly Diagnosed High-intermediate And High Risk DLBCL Patients

    Jacksonville, FL, Rochester, MN

  5. MC230813 A Study Of Golcadomide With Rituximab Prior To CAR-T With Relapsed Or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

  6. A Dose-Escalation And Expansion Study Of Tacabrutideg (BGB-16673) In Participants With B-Cell Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Extracorporeal Photopheresis And Mogamulizumab For The Treatment Of Erythrodermic Cutaneous T Cell Lymphoma

    Scottsdale/Phoenix, AZ

  8. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

    Scottsdale/Phoenix, AZ

  9. A Study To Evaluate Brentuximab Vedotin Or Placebo In Combination With Lenalidomide And Rituximab In Subjects With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    Rochester, MN

  10. Study Of Bcl-2 Inhibitor BGB-11417 In Participants With Mature B-Cell Malignancies

    Rochester, MN

.

Mayo Clinic Footer